Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors

PURPOSE: Ridaforolimus is a non-prodrug mTOR inhibitor. The safety, pharmacokinetics (PK), and antitumor activity of oral ridaforolimus were assessed in Japanese patients with refractory solid tumors. METHODS: Ridaforolimus (20 or 40 mg) was administered as a single dose on Day 1, followed by once d...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Seki, Yoshitaka, Yamamoto, Noboru, Tamura, Yosuke, Goto, Yasushi, Shibata, Takashi, Tanioka, Maki, Asahina, Hajime, Nokihara, Hiroshi, Yamada, Yasuhide, Shimamoto, Takashi, Noguchi, Kazuo, Tamura, Tomohide
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer-Verlag 2011
Témata:
Clinical Trial Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3313018/
https://ncbi.nlm.nih.gov/pubmed/22143378
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-011-1788-4
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky